Legal and regulatory experts expect litigation to arise if the FDA seeks to enforce its pharma DTC ad crackdown, though how it might play out is nuanced.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback